Gd-EOB-DTPA动脉期呼吸伪影与患者临床指标的相关性研究

doi:10.12117/jccmi.2020.02.008

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the correlation between respiratory artifacts in Gadoxetate disodium(Gd-EOB-DTPA) arterial phase and clinical indicators such as liver cirrhosis and liver function. Methods: A total of 92 patients with Gd-EOB-DTPA enhancement underwent arterial respiratory artifact scoring, with moderate to severe respiratory artifacts(TSM) defined as≥3 points, and patients are grouped by gender(male, female), age(youth, middle-aged, old-aged), BMI(normal, overweight, obese), blood pressure(normal, normal high, high blood pressure), liver function(grade A and B), cirrhosis(with or without cirrhosis). The incidence of moderate to severe artifacts in Gd-EOB-DTPA arterial phase was analyzed, and the correlation between the above group and moderate to severe respiratory artifacts was analyzed by single-factor chi-square test and multi-factor binary logistic regression. Results: The incidence of moderate to severe artifacts in this group was 50%. The single-factor chi-square test, Pearson chi-square test, and Fisher’s exact test showed that age, gender, BMI, cirrhosis, liver function, and blood pressure were not associated with moderate to severe respiratory artifacts(P values were 0.650, 0.501, 0.406, 0.402, 0.406, 0.649, respectively, P>0.05); further multivariate logistic regression analysis and Wald test did not show statistical significance(P>0.05). Conclusion: Gd-EOB-DTPA has a higher incidence of arterial respiratory artifacts, but it has no correlation with clinical indicators(age, gender, BMI, cirrhosis, Child-Pugh classification and blood pressure), suggesting that it may be related to the side effects.

Key words： Liver Magnetic resonance imaging

Received: 22 May 2019

PACS:	Ｒ575
	Ｒ445.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Yong-qian
	ZHAO Xin-xiang

Cite this article:

LIU Yong-qian,ZHAO Xin-xiang. Correlation between respiratory artifacts in Gd-EOB-DTPA arterial phase and clinical indicators of patients[J]. JOURNAL OF CHINA MEDICAL IMAGING, 2020, 31(2): 106-110.

URL:

http://www.jccmi.com.cn/EN/10.12117/jccmi.2020.02.008 OR http://www.jccmi.com.cn/EN/Y2020/V31/I2/106

[1]Xiao YD, Ma C, Liu J, et al. Transient severe motion during arterial phase in patients with Gadoxetic acid administration: Can a five hepatic arterial subphases technique mitigate the artifact?[J]. Exp Ther Med, 2018, 15(3): 3133-3139.
[2]Furlan A, Close ON, Borhani AA, et al. Respiratory-motion artefacts in liver MRI following injection of gadoxetate disodium and gadobenate dimeglumine: an intra-individual comparative study in cirrhotic patients[J]. Clin Radiol, 2017, 72(1): 93.e1-93.e6.
[3]Bashir MR, Gupta RT, Davenport MS, et al. Hepatocellular carcinoma in a North American population: does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis?[J]. J Magn Reson Imaging, 2013, 37(2): 398-406.
[4]Chung YE, Kim MJ, Kim YE, et al. Characterization of incidental liver lesions: comparison of multidetector CT versus Gd-EOB-DTPA-enhanced MR imaging[J]. PloS one, 2013, 8(6): e66141.
[5]Well L, Weinrich JM, Adam G. Transient Severe Respiratory Motion Artifacts After Application of Gadoxetate Disodium: What We Currently Know[J]. Rofo, 2018, 190(1): 20-30.
[6]Bashir MR, Castelli P, Davenport MS, et al. Respiratory motion artifact affecting hepatic arterial phase MR imaging with gadoxetate disodium is more common in patients with a prior episode of arterial phase motion associated with gadoxetate disodium[J]. Radiology, 2015, 274(1): 141-148.
[7]Davenport MS, Viglianti BL, Al-Hawary MM, et al. Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality[J]. Radiology, 2013, 266(2): 452-461.
[8]Pietryga JA, Burke LM, Marin D, et al. Respiratory motion artifact affecting hepatic arterial phase imaging with gadoxetate disodium: examination recovery with a multiple arterial phase acquisition[J]. Radiology, 2014, 271(2): 426-434.
[9]Kim SY, Park SH, Wu EH, et al. Transient respiratory motion artifact during arterial phase MRI with gadoxetate disodium: risk factor analyses[J]. AJR, 2015, 204(6): 1220-1227.
[10]Davenport MS, Bashir MR, Pietryga JA, et al. Dose-toxicity relationship of gadoxetate disodium and transient severe respiratory motion artifact[J]. AJR, 2014, 203(4): 796-802.
[11]Davenport MS, Caoili EM, Kaza RK. Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumine[J]. Radiology, 2014, 272(1): 123-131.
[12]McClellan TR, Motosugi U, Middleton MS, et al. Intravenous Gadoxetate Disodium Administration Reduces Breath-holding Capacity in the Hepatic Arterial Phase: A Multi-Center Randomized Placebo-controlled Trial[J]. Radiology, 2017, 282(2): 361-368.
[13]Hayashi T, Saitoh S, Tsuji Y, et al. Influence of Gadoxetate Disodium on Oxygen Saturation and Heart Rate during Dynamic Contrast-enhanced MR Imaging[J]. Radiology, 2015, 276(3): 756-765.
[14]Motosugi U, Bannas P, Bookwalter CA, et al. An Investigation of Transient Severe Motion Related to Gadoxetic Acid-enhanced MR Imaging[J]. Radiology, 2016, 279(1): 93-102.
[15]Well L, Rausch VH, Adam G, et al. Transient Severe Motion Artifact Related to Gadoxetate Disodium-Enhanced Liver MRI: Frequency and Risk Evaluation at a German Institution[J]. Rofo, 2017, 189(7): 651-660.
[16]Shah MR, Flusberg M, Paroder V, et al. Transient arterial phase respiratory motion-related artifact in MR imaging of the liver: an analysis of four different gadolinium-based contrast agents[J]. Clin Imaging, 2017, 41: 23-27.
[17]Park YS, Lee CH, Yoo JL, et al. Hepatic Arterial Phase in Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging: Analysis of Respiratory Patterns and Their Effect on Image Quality[J]. Invest Radiol, 2016, 51(2): 127-133.
[18]Kanki A, Tamada T, Abe T, et al. Relationship between transient severe motion of the liver in gadoxetic acid or iodinated contrast agent-enhanced imaging and arterial oxygen saturation and heart rate changes[J]. Magn Reson Imaging, 2018, 53: 77-81.
[19]Song JS, Choi EJ, Park EH. Comparison of transient severe motion in gadoxetate disodium and gadopentetate dimeglumine-enhanced MRI: effect of modified breath-holding method[J]. Eur Radiol, 2018, 28(3): 1132-1139.
[20]Polanec SH, Bickel H, Baltzer PA, et al. Respiratory motion artifacts during arterial phase imaging with gadoxetic acid: Can the injection protocol minimize this drawback?[J]. J Magn Reson Imaging, 2017, 46(4): 1107-1114.
[21]McQueen DS, Ritchie IM. Arterial chemoreceptor involvement in salicylate-induced hyperventilation in rats[J]. Br J Pharmaco, 1989, 98(2): 413-424.